At eyeforpharma Philadelphia 2019, our speakers are pioneering experts in their field of expertise.
Chris Sellin Head of Operational Excellence & Analytics Shire
Greg Apostol National Vice President, Key Account Management Alkermes
Greg leads the Key Account Management and Field Reimbursement team at Alkermes. Prior to joining in 2018, Greg has held leadership positions across pharma, bringing 20+ years of industry experience, most recently as Vice President of Key Account Management at Astellas. Prior to joining Astellas, Apostol worked for 18 years at Pfizer, launching and leading the Key Account Management (KAM) team, as well as leadership roles in Primary Care and Institutional Sales, Specialty Sales, Payer Account Management, and in KAM. Apostol has extensive domestic and international experience focused on improving clinical and quality outcomes for patients through Integrated Delivery Network (IDN) marketing, organized customer market strategies and KAM training platforms. Apostol is a graduate of Colby College of Waterville, Maine, where he earned a bachelor's degree in business and history. He also holds a Master of Science in Health Systems from Rutgers and a Masters Certificate from Villanova in Lean Six Sigma, Six Sigma Green Belt and Project Management.
David Fortanbary Head of North America Commercial Training UCB
Tosh Butt Vice President, Sales for Primary Care and Respiratory Specialty AstraZeneca
James Brewer Director of Global Commercial Operations Marketing Platforms Eli Lilly
Matt Portch Vice President, Managed Markets Sunovion
Emmanuel Fombu Director, Digital Medicines Novartis
Debra Hussain Senior Director of Marketing - Multi-Channel Team Leader Eli Lilly
Kirk Keaffaber Senior Marketing Director Eli Lilly
Matthew Smith Global Strategy Lead Pfizer
Peter Barschdorff Vice President, Commercial Insights GSK
Rahul Avasthy Digital Transformation Lead Abbott
Magdalena Schoeneich Global Head, Digital Accelerator, R&D Takeda
Jodie Sherman Gillon Global Medical Lead, Patient Engagement Rare Diseases Pfizer
Amy Nicole Nayar Head of Global Patient Relations Abbvie
Peter Stueckemann Head of Patient Experience & Value UCB
Anthony Yanni Head, Medical Intelligence and Patient Perspectives Sanofi
Cynthia Dilley Head of New Patient Value Focus UCB
Robert Cuddihy Vice President U. S. Medical Affairs Amgen
Lauren Millette Director Medical Alignment AstraZeneca
Robin Winter-Sperry Head, Global Field Based Medical Excellence & Insights Sanofi
Jimmie Overton Associate Vice President Global Medical Scientific Information and Library Allergan
Victoria Ho WW Field Medical & Communications Lead Bristol Myers-Squibb
Mike Spencer Vice President Market Access Oncology Janssen
Muna Bhanji SVP, Senior Vice President, Global Market Access & Policy Merck
Muna Bhanji serves as head of Merck’s Global Market Access organization with responsibility for enabling access and payer reimbursement for the company’s medicines and vaccines.
Throughout her career, Muna has demonstrated an unwavering commitment to Merck’s mission of saving and improving lives, working with healthcare providers, patients and payers to support access to the inventions brought forward by Merck’s scientists.
Muna joined Merck’s Manufacturing Division in 1986 and later transitioned to Merck's Human Health group where she has held positions of increasing responsibility in the areas of Sales, Managed Markets, Commercial Operations and Global Marketing for Hospital & Specialty businesses including Oncology, Virology, Anti-infective, Neuroscience and Immunology franchises. Since 2012, Muna, in her capacity as head of Global Market Access, leads the Pricing and Market Access Strategy functions for Merck’s diverse portfolio of products and vaccines, globally.
In addition to her commercial leadership roles, she has served on the Board of the Foundation of Managed Care Pharmacy and has chaired Merck’s Supervisory Board in the Netherlands. She is currently on the Board of Possible Health, a Nepal focused NGO, providing integrated, high quality, affordable healthcare to rural, underserved communities.
Muna earned her Bachelor of Pharmacy degree from Rutgers School of Pharmacy and an MBA from St. Joseph’s University.
Robert Dubois Executive Vice President and Chief Science Officer National Pharmaceutical Council
Robert W. Dubois, MD, PhD, is the chief science officer and executive vice president of the National Pharmaceutical Council (NPC). In this role, he oversees NPC’s research on policy issues related to the appropriate role of real-world evidence in decision-making, how best to determine value of health care services, the relationship between access and health outcomes, and approaches to maintain an environment supportive of innovation.
Dr. Dubois, who is board certified in internal medicine, brings more than 25 years of experience in health care research, with a particular focus on understanding and ensuring that patients receive high value health care. He has co-founded and led various health care research organizations in developing quality research with practical application. Most recently, he was the chief medical officer at Cerner LifeSciences, where he focused on comparative effectiveness and the use of an electronic health records infrastructure to implement clinical change.
Prior to joining Cerner in 2001, Dr. Dubois co-founded Protocare Sciences and was its executive vice president, chief medical officer, and later its CEO.
Throughout his career, Dr. Dubois’ primary interest has centered on defining “what works” in health care and finding ways for that evidence to inform health care decision-making. He is a recognized expert in the areas of defining best practice, disease management and appropriateness of care. He has authored more than 160 peer-reviewed articles on comparative effectiveness, evidence-based medicine, the development of practice guidelines and determining the optimal use of high-cost medical services.
Dr. Dubois received his AB from Harvard College, his MD from the Johns Hopkins School of Medicine and his PhD in health policy from the RAND Graduate School. He is a member of the Medicare Evidence Development and Coverage Advisory Committee, Steering Committee for the Electronic Data Methods Forum, and the Advisory Board of the Institute for Clinical and Economic Review. Additionally, he is the associate editor of the Journal of Comparative Effectiveness Research and is on the editorial board for Health Affairs and The American Journal of Managed Care.
Jenny McNair Senior Medical Director Aetna
Dr. McNair joined Aetna in September 2017 and brings a wealth of healthcare experience.
A hospitalist by training, Dr. McNair has significant experience in UM/UR for commercial, Medicare, and MA plans, as well as care management. As a physician leader, she has managed teams of physicians and healthcare providers, spurring them to excellence.
As the Senior Medical Director for Aetna Community Care, Dr. McNair is devoted to achieving the best outcomes possible and reducing barriers to wellbeing within a high risk population. These goals are achieved through a variety of means, including collaborating with staff, providing ongoing education both clinically and related to care management, and multidisciplinary case conferences. She works closely with other Aetna programs to ensure a seamless, high-quality member experience. Further, her interactions with providers, provider groups, and medical neighborhoods promotes member engagement, success, and provider satisfaction. She has a special interest in informatics and data visualization and uses this interest to assess program efficacy and identify areas of opportunity.
Dr. McNair graduated from the University of Texas Health Science Center in San Antonio and completed her residency at Wake Forest Baptist Medical Center in North Carolina. She is board certified in Internal Medicine.
Lynn Taylor Senior Vice President, Head of Global Healthcare Government & Public Affairs, Head of Corporate & Governmentt Relations USA EMD Serono
Lynn Taylor is an accomplished global corporate affairs executive, bringing over twenty years of experience in the healthcare industry. She is an experienced and dynamic leader, known for effectively navigating and succeeding in the corporate, trade association, policy, advocacy, and political realms. Lynn has a passion and proven track record for building, transforming, inspiring, and leading teams on a global basis to bring value to patients, governments, civil society, and business.
Lynn serves as Head of Healthcare Global Government & Public Affairs and Head of Corporate & Government Relations, USA. In her role as Head of Healthcare Global Government & Public Affairs, Lynn positions the Healthcare sector as the partner of choice to ensure new medicines are brought to patients around the world to help create, improve and prolong life. Lynn and her team work on a global basis to shape government public policies, enhance the company’s reputation and build relations and partnerships with key external stakeholders, including with patient groups and professional societies.
In her capacity as Head of Corporate and Government Relations, USA, Lynn is responsible for leading the company’s engagement with external stakeholders based in the USA on behalf of the company’s three business sectors: Healthcare; Life Science; and, Performance Materials. Lynn is responsible for positioning the company as a leading science and technology company to positively impact public policy on cross-cutting topics and corporate reputation.
Lynn joined the company in 2005 as Executive Director of US Government Relations, became Vice President of US Government Affairs and Head of the Washington, DC Office in 2006, and assumed the role of Senior Vice President and Head of Global Government Affairs and Policy for the Healthcare sector in 2013.
Lynn joined the biopharmaceutical industry in 1997. She began her industry career in the field of health outcomes research working at MEDTAP International (currently UBC – An Express Scripts Company), where she conducted cost-effectiveness, cost-of-illness, and quality-of-life research on a broad range of disease areas for both pharmaceuticals and medical devices. She then took a variety of roles of increasing scope and responsibility in the areas of strategy, health policy, and government relations at the Pharmaceutical Research and Manufacturers of America (PhRMA), DEKA Research and Development, and Millennium Pharmaceuticals (currently Millennium: The Takeda Oncology Company).
Lynn serves as Chairman of the German American Business Council (GABC) of Washington, DC, an independent, non-profit organization that fosters transatlantic business dialogue between Germany and the USA. Lynn is also a member of the Board of Governors of the Bryce Harlow Foundation and the Board of Directors of Healthy Women. The Bryce Harlow Foundation is a Washington, DC based not-for-profit organization dedicated to promoting the highest standards within the profession of lobbying and government relations. Healthy Women is the leading not-for-profit in the USA dedicated to improving women’s health, both educating and empowering women to make informed health choices for themselves and their families and ensuring that women's health is a primary focus by policy makers and advocacy groups.
Lynn earned her master’s degree in public administration from American University in Washington, DC and her bachelor’s degree in political science from Fordham University in New York. She is married with two children and is based in Washington, DC.
Sonal Bhatia Vice President, North America Medical Lead, Rare Diseases Pfizer
Jennifer Wong Senior Director, RWE Strategy & Alliances, Global Medical Affairs AstraZeneca
Sai Jasti Commercial Data Officer GSK
Percival Barretto-Ko President, US Astellas
Percival Barretto-Ko is president, Astellas Americas. In this role, he has responsibility for the company's operations across the Americas region of Astellas, a company dedicated to improving the health of people around the world through the provision of innovative pharmaceutical products. Astellas focuses on serving patients’ unmet medical needs across multiple therapeutic areas, including Cardiology, Hematology, Immunology, Infectious Diseases, Oncology and Urology.
Previously, Barretto-Ko was senior vice president, international, where he led Astellas Pharma Canada, Astellas Farma Brasil, Astellas Farma Colombia and operations in more than 20 other countries where Astellas’ innovative therapies serve unmet patient needs.
Barretto-Ko joined Astellas in 2005 in the United Kingdom, initially leading the company’s Immunology and Transplantation business unit in Europe, the Middle East and Africa, and thereafter, led Astellas Pharma Europe’s corporate strategy organization. In 2011, he returned to the US as Senior Vice President, corporate strategy and government affairs. In that role, Barretto-Ko led the company’s corporate strategy and business development organizations based in Northbrook, Ill., and government affairs based in Washington, D.C.
Before joining Astellas, Barretto-Ko held commercial positions with the Roche Group in the United States and United Kingdom.
Barretto-Ko earned a B.S. in biological sciences with honors from Cornell University, an MBA from Yale School of Management and an M.S. from MIT Sloan School of Management, where he also served as a Sloan Fellow for Innovation and Global Leadership.
In addition, Barretto-Ko serves on the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) and represents Astellas on PhRMA’s Federal Committee, which helps shape how PhRMA approaches key policy issues on Capitol Hill.
Marc Boutin President National Health Council
Anders Dyhr Toft Corporate VP, Commercial Innovation (Digital Health, Patient Support Programmes and Devices) Novo Nordisk
Ben Wiegand, PhD. Global Head, World Without Disease Accelerator Janssen Research & Development, LLC
As Head of the Disease Interception Accelerator (DIA), Ben Wiegand, Ph.D., leads a team focused on addressing the root causes of select diseases, intervening earlier than today’s clinically accepted point of diagnosis to stop, reverse or inhibit progression to disease.
With more than 20 years at Johnson & Johnson (J&J), Ben brings a range of experience in identifying and piloting new business and funding models, accelerating growth opportunities and scouting new and emerging scientific areas to deliver innovative solutions.
Prior to joining the DIA, Ben served as Vice President, Global Open Innovation and New Business Models Research & Development for the J&J Group of Consumer Companies. His responsibilities included the creation of disruptive innovations and the progression of emerging scientific areas, like the microbiome and big data, to progress advances in healthcare.
Ben has served as General Manager and Vice President, Science and Innovation, J&J Wellness & Prevention, Inc. He also held responsibility for the Employer Franchise, focused on providing health and performance solutions to large employers to help manage healthcare costs and improve employee productivity. During his tenure with Wellness & Prevention, Ben led science and innovation efforts to support the enterprise, including oversight of an innovation development program and measurement/reporting of industry-leading organizational outcomes.
Ben earned a Bachelor of Science in Chemistry from the University of Illinois and a Master of Arts and a Ph.D. in Physical Chemistry from Harvard University.
Michelle Carnahan Head of North America Diabetes & Cardiovascular and Interim Head of North America General Medicines & Established Products Sanofi
As the North America Head of the Primary Care Business Unit for Sanofi, Michelle is responsible for commercial operations in the U.S. (including Puerto Rico) and Canada, which is comprised of Sales, Marketing, Market Access, One Trade, and Innovative Solutions. Michelle also sits on the Board of Directors for Onduo, a joint venture with Verily Life Sciences dedicated to helping people living with diabetes. She will also serve as the Chair for Sanofi’s U.S. Country Council starting on January 1, 2019
Michelle has a broad commercial background which includes substantial P&L accountability, extensive partnerships, significant organizational results, and strategic innovation work. Throughout her career, she has demonstrated her skills as a passionate, patient-centric leader who consistently holds herself and the organization to drive outcomes and better experiences for patients. She joined Sanofi in January 2018, bringing deep knowledge across many therapeutic areas including CNS, women’s health, musculoskeletal and diabetes. During her 25 years with Eli Lilly, she held progressively more senior roles in sales, marketing, human resources, and general management. Most recently, Michelle served as Chief Operating Officer for the International Business of Lilly, where she was responsible to drive the commercial operations and strategy.
Michelle is recognized for championing women’s issues and education. She is one of the Sanofi ambassadors for the Healthcare Businesswomen’s Association Gender Parity Collaborative. She served as executive sponsor of Lilly’s Women’s Leadership Network for several years. She also served as a member of the Advisory Council for St. Mary’s Child Center, is currently an Advisor to the JBW Women in Management Center at Purdue University, and serves on the Alumni Board at DePauw University.
She is also member of the Health Leadership Council, an exclusive coalition of healthcare executives aiming to help make affordable, high-quality care accessible to all.
Michelle earned her Bachelor of Arts in Economics from DePauw University.
Anthony Gucciardo SVP, Strategic Partnerships National Kidney Foundation
Tom Croce VP, Global Advocacy Relations Amgen
Scott Williams VP, Head of Global Patient Advocacy and Strategic Partnerships EMD Serono
Steven Hildemann SVP, Patient Safety and Chief Medical Officer Merck KGaA Darmstadt
Chapman Richardson Global Head of Data Consumerization Sanofi
Diane Moniz Executive Director and Head, Strategic Collaborations, U.S. Medical Bristol-Myers Squibb
Michele Sharp Senior Director, Regulatory Affairs Eli Lilly
Michele Sharp received her Doctor of Pharmacy degree from Butler University in Indianapolis, Indiana in 1994. She started her pharmaceutical career as a hospital pharmacist at Methodist Hospital in Indianapolis. In 1995, Michele joined Eli Lilly and Company where her career has spanned across 4 different assignments in the organization, including US Medical Affairs and Global Regulatory Affairs. Her experience in Regulatory Affairs includes leading label development for several US New Drug Applications, serving as the liaison between a Lilly product development team and the Food and Drug Administration (FDA) to obtain regulatory approvals for new formulations and indications for the product, and supervising a group of 20 Regulatory reviewers who review all advertising and promotional materials for over 20 US marketed products. In this role, she has worked to develop mutually productive relationships with the leaders within the FDA Office of Prescription Drug Promotion. Michele has presented oral testimony on behalf of Lilly at FDA hearings and participated on expert panels at various professional conferences on topics ranging from health information technology and challenges in advertising and promotion for prescription drugs, how to leverage the Targeted Product Profile (TPP) tool during the drug development process to maximize efficiencies in both drug development and commercial phases, ways to apply a quality system framework in the development, dissemination and maintenance of advertising and promotion and incorporating health literacy principles during development of consumer safety information for consumer-directed advertising.
Shontelle Dodson Senior Vice President, Healthcare Systems Astellas
Tamar Thompson Head, Federal Payment Policy & State Government Affairs/Alliance Development Bristol-Myers Squibb
Shurjeel Choudhri Senior Vice President and Head, Medical and Scientific Affairs Bayer
Drew Suiter Associate Director, Hospital Systems Genentech
Kyle Skiermont Chief Operating Officer Fairview Pharmacy Services
Kyle Skiermont is the Chief Operating Officer for Fairview Pharmacy Services, a leading health system based pharmacy organization in Minneapolis, MN. He received his PharmD from the University of Nebraska Medical Center College of Pharmacy. As COO, Kyle is responsible for strategy and overall operations of Fairview Pharmacy's specialty pharmacy, retail, MTM, mail order, long term care, compounding, home infusion and community infusion business units.
Kyle has spent 20+ years in pharmacy including traditional retail, clinic based retail, outpatient pharmacy at an academic health center, community and home infusion, specialty, and mail order. In addition, he is a frequent media and professional spokesperson on a variety of pharmacy topics.
Stephen Basilotto Chief Experience Officer Froedtert Health
Steve Basilotto serves as chief experience officer for Froedtert Health, charged with identifying and executing leading edge opportunities to provide customers, patients and staff with an experience they want and value. Steve draws upon his 30 years of pairing a people-centric approach with technology and analytics to deliver consumer-guided innovations. His additional responsibilities for corporate marketing, communications, strategic planning, performance measurement, innovation and a digital health company for Froedtert Health, directly support the creation of an atmosphere of engagement and discovery.
Steve’s direct-to-customer experience spans financial services, health insurance, technology and now health provision services. In recent years, he served as head of enterprise consumer experience and consumer service operations for Aetna. Previously, Steve was COO of USAA Bank, a US financial services firm consistently recognized at the top of Forrester’s annual US Customer Experience Index. Prior to USAA, Steve held senior leadership positons in operations, technology, analytics and strategy at HSBC, GE Capital and Fidelity Investments.
Steve’s refreshing approach inspires purpose-driven customer interactions grounded in respect, possibility and fun. His team members describe his leadership style as emotionally intuitive and collaborative. In describing his own leadership philosophy, Steve says “Everyone benefits when we align our strengths with dynamic business opportunities. I set high standards but empower and trust my team with the next challenge.”
An adventure-seeking family man, Steve loves his time with his wife and son, including playing or watching sports and trying new restaurants. His interest in classic and exotic cars hints at his passion for innovation.
Froedtert Health is a Milwaukee, Wisconsin-based integrated health care system providing a variety of health-related services including hospitals and health centers, home care, laboratory, health insurance, employer health services and workplace clinics, and digital health solutions. Froedtert Health combines with the Medical College of Wisconsin to offer five hospitals, more than 1,600 physicians and nearly 40 health centers and clinics in southeast Wisconsin, drawing patients from throughout the Midwest and the nation.
Zach Weinberg Co-founder, President and COO Flatiron Health
Peter Anastasiou Executive Vice President, North America Lundbeck
Mike Zeglinski Senior Vice President, Specialty Pharmacy OptumRx
Greg Apostle National VP, KAM Alkermes
Francois Motyl Global Digital Governance Lead Novartis
Helena Chung Patient Engagement Director for Oncology AstraZeneca
Jessica Nora Head, Patient Engagement Strategy Amgen
Mary Brown President, CEO Sickle Cell Disease Foundation of California
Michelle Rice Senior Vice President External Affairs National Hemophilia Foundation